Results 191 to 200 of about 215,509 (321)

THE USE OF CULTURE MEDIA MADE FROM COMMERCIAL DRIED YEAST AS A ROUTINE SUBSTITUTE FOR MEAT INFUSION PEPTONE MEDIA [PDF]

, 1929
James M. Neill, John Y. Sugg, Lurline V. Richardson, William L. Fleming   +3 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Bioaccessibility and Biological Activities of Phytochemicals from Wild Plant Infusions and Decoctions Before and After Simulated In Vitro Digestion. [PDF]

Plant Foods Hum Nutr
Monari S, Ferri M, Zappi A, Escórcio R, Correia VG, Cairrão A, Bento A, Pereira CS, Tassoni A.   +8 more
europepmc   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Phenolic profiles and antioxidant activity of Morus alba L. infusions prepared from commercially available products and naturally collected leaves. [PDF]

Sci Rep
Janiak MA, Gryn-Rynko A, Sulewska K, Amarowicz R, Penkacik K, Graczyk R, Olszewska-Słonina D, Majewski MS.   +7 more
europepmc   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Dissociation of intake and incentive sensitization during intermittent- and continuous-access heroin self-administration in rats. [PDF]

Psychopharmacology (Berl)
Rakowski EA, King CP, Thompson BM, Santos G, Holmes E, Solberg Woods LC, Polesskaya O, Palmer AA, Meyer PJ.   +8 more
europepmc   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. [PDF]

Oncologist
Fletcher K, Rehman S, Irlmeier R, Ye F, Johnson D.   +4 more
europepmc   +1 more source

Infusion cholecystography

Journal of British Surgery, 1985
K R, Poskitt, I F, Lane, A D, Taylor, T, Cooke   +3 more
openaire   +2 more sources